Precipio Inc. (PRPO) reports $7.0M quarterly revenue record as adjusted EBITDA turns positive
NEW HAVEN, Aug 14. Revenue of $7.0 million in the second quarter set a quarterly record for Precipio, Inc. (NASDAQ: PRPO), the specialty cancer diagnostics company disclosed in an 8-K filed with the Securities and Exchange Commission. The result was up 22% year over year from $5.7 million in Q2-2025 and above the prior quarter's $6.7 million.
Key takeaways
- Precipio, Inc. (NASDAQ: PRPO) reported record quarterly revenue of $7.0 million in Q2, up 22% year over year from $5.7 million in Q2-2025 and above the prior quarter's $6.7 million.
- Adjusted EBITDA turned positive at $0.4 million, reversing a $0.2 million loss in Q1-2026, driven by a $0.3 million revenue increase and a $0.2 million reduction in stock-based compensation.
- On a GAAP basis, Precipio posted a net loss of $0.2 million for the quarter, compared with net income of $0.1 million in Q2-2025.
- Total cash increased $0.5 million to above $3 million at quarter-end, up from $1.1 million a year earlier, with $0.7 million in operating cash flow and no financing event.
- Pathology revenue was $6.1 million and product revenue reached $0.9 million, the latter up 21% from its previous high of $750,000 in Q4-2025.
NEW HAVEN, Aug 14. Revenue of $7.0 million in the second quarter set a quarterly record for Precipio, Inc. (NASDAQ: PRPO), the specialty cancer diagnostics company disclosed in an 8-K filed with the Securities and Exchange Commission. The result was up 22% year over year from $5.7 million in Q2-2025 and above the prior quarter's $6.7 million.
Adjusted EBITDA turned positive at $0.4 million after a loss of $0.2 million in Q1-2026. Precipio said the swing was driven by a $0.3 million revenue increase and a $0.2 million reduction in stock-based compensation expense. On a GAAP basis the company posted a net loss of $0.2 million for the quarter, against net income of $0.1 million in Q2-2025.
Revenue and cash
Pathology revenue, the larger of Precipio's two segments, came in at $6.1 million, up from $6.0 million in Q1-2026. Product revenue reached $0.9 million, against $0.66 million the prior quarter. The company said product revenue rose 21% from its previous high of $750,000 posted in Q4-2025.
Operating cash flow was $0.7 million in Q2-2026. Total cash increased $0.5 million over the period, leaving the quarter-end balance above $3 million. A year earlier the cash balance stood at $1.1 million.
The GAAP-to-adjusted reconciliation records stock-based compensation of $0.8 million in Q2-2026, double the $0.4 million in Q2-2025. Amortization of intangibles held at $0.2 million in both periods. Precipio also recorded $0.4 million in other significant income during the quarter; both items are excluded from the adjusted EBITDA figure. Non-GAAP EBITDA before those further adjustments was breakeven in Q2-2026, against $0.4 million in Q2-2025.
Chief Executive Ilan Danieli said the cash balance climbed above $3 million without a financing event, which he described as demonstrating the strength of operations. He said the company believes it is well positioned to continue building on the quarter's momentum. Precipio also filed its Form 10-Q for the period the same day.
Management is scheduled to discuss Q2 performance on a shareholder call August 17, 2026, at 5 p.m. Eastern time, with a moderated Q&A to follow.